Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma.
Peak TC, Fenu EM, Rothberg MB, Thomas CY, Davis RL, Levine EA. Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma. Case Rep Urol. 2020; 2020:8846135.